hVIVO plc Directors' Dealings (2819M)
October 12 2016 - 2:00AM
UK Regulatory
TIDMHVO
RNS Number : 2819M
hVIVO plc
12 October 2016
For immediate release 7.00am: 12 October 2016
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with
clinical testing capabilities, announces that application has been
made to AIM for the admission of 10,767 new ordinary shares of 5.0p
each in the Company (the "New Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jaime Ellertson (Non-Executive Chairman) and Jim
Winschel (Non-Executive Director) of new ordinary shares, under the
terms of their letters of appointment as set out in the Company's
announcement of 4 November 2014 which stated that Mr Ellertson and
Mr Winschel had entered into binding commitments to purchase
$20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively
per quarter. The New Ordinary Shares represent their investments
for the quarter ended 30 September 2016. On 11 October 2016, Mr
Ellertson invested in an additional 8,546 ordinary shares and Mr
Winschel invested in an additional 2,221 ordinary shares, at a
price of 180.1 pence per share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 78,101,077 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 17 October 2016. Following
Admission, Mr Ellertson and Mr Winschel will be interested in a
total of 55,040 and 34,706 ordinary shares of 5.0p in the Company
respectively, each representing less than 0.1% of the Company's
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
--- -------------------------------------------------------------------------
a) Name Jaime Ellertson and Jim Winschel
--- ------------------------- ----------------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------------
a) Position/ Non-Executive Chairman and Non-Executive
status Director
--- ------------------------- ----------------------------------------------
b) Initial notification/ Initial Notification
Amendment
--- ------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -------------------------------------------------------------------------
a) Name hVIVO plc
--- ------------------------- ----------------------------------------------
b) Legal Entity N/A
Identifier
--- ------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--- -------------------------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the financial
instrument,
type of instrument GB00B6ZM0X53
Identification
code
--- ------------------------- ----------------------------------------------
b) Nature of Acquisition of ordinary shares
the transaction
--- ------------------------- ----------------------------------------------
c) Currency GBP
--- ------------------------- ----------------------------------------------
d) Price(s) and Director Price (p) Volume
volume(s) ----------------- ---------- -------
Jaime Ellertson 180.1 8,546
----------------- ---------- -------
Jim Winschel 180.1 2,221
----------------- ---------- -------
--- -------------------------
e) Aggregated
information
- Aggregated
volume
- Price 10,767
- Aggregated 180.1p
total
GBP19,391.37
--- ------------------------- ----------------------------------------------
f) Date of the 11 October 2016
transaction
--- ------------------------- ----------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--- ------------------------- ----------------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with clinical
testing capabilities, is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV, and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 45 clinical studies,
inoculated over 2000 volunteers and has three first-in-class
therapies currently in development with a growing pre-clinical
pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGWGUUPQPUG
(END) Dow Jones Newswires
October 12, 2016 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024